Please login to the form below

Scottish Medicines Consortium

This page shows the latest Scottish Medicines Consortium news and features for those working in and with pharma, biotech and healthcare.

Novartis’ MS therapy Mayzent approved by NICE

Mayzent (siponimod), a sphinogosine 1-phosphate receptor modulator, is the first oral disease-modifying treatment recommended by both NICE and the Scottish Medicines Consortium (SMC) for SPMS with active disease.

Latest news

Shionogi launches thrombocytopenia treatment Mulpleo in the UK

The UK’s medicines watchdog NICE and the Scottish Medicines Consortium recently backed the use of Mulpleo in this patient population after determining that the drug was cost-effective.
SMC enables access to Kyowa Kirin’s Crysvita for rare bone disease

Drug is being reviewed under new ultra-orphan pathway. The Scottish Medical Consortium has enabled access to Japanese pharma Kyowa Kirin's Crysvita, a novel treatment for a rare inherited bone ... England’s cost-effectiveness watchdog NICE issued a
Diurnal files adrenal insufficiency drug Alkindi in US

It has since been backed by the Scottish Medicines Consortium (SMC) for reimbursement on the NHS.
Vertex scores CF deal with Scotland, but access debate continues

Pressure to reach a deal in England mounts. Following an initial rejection from the Scottish Medicines Consortium (SMC), Vertex has reached an agreement for all eligible cystic fibrosis patients living in ... The agreement has been reached after
Novartis’ CAR-T Kymriah scores SMC approval

Will now be available on NHS across the UK. Novartis’ Kymriah (tisagenlecleucel) has received routine reimbursement for all eligible UK patients on the NHS, following appraisal from the Scottish Medicines Consortium. . ... treatments. The medicine

More from news
Approximately 5 fully matching, plus 88 partially matching documents found.

Latest Intelligence

The Orkambi row explained

December 2018: Scottish Government agrees a deal with Vertex pending submission of Orkambi and Symkevi to Scottish Medicines Consortium (SMC), with interim access possible through the PACS Tier 2 system. ... March 2019: Vertex, NHSE and NICE meet with
The reality of real-world evidence

Zaltrap re-submission to the Scottish Medicines Consortium (SMC) included RWE (pooled data from two open-label, single-arm studies) to demonstrate prolonged safety and QoL benefit.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Account Management: Competitive Salary Offered

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Senior Content Editor - Biotechnology: Salary TBC

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Principal Medical Writer: Varies on experience

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

PMHub

Add my company

Aurora Healthcare Communications

We're a leading healthcare strategic communications agency helping pharmaceutical companies adapt fast to improve the lives of patients and healthcare...

Latest intelligence

Virtual congresses: video thrilled the cardio tsar: Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?: The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.: Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....